8. NCCN Guidelines with NCCN Evidence Blocks for Non-Small Cell Lung Cancer V.4.2016. www.NCCN.org (registration required)
9. June-Koo Lee, MD, Seokyung Hahn, PhD, Dong-Wan Kim, MD, PhD, Koung Jin Suh, MD, Bhumsuk Keam, MD, Tae Min Kim, MD, PhD, Se-Hoon Lee, MD, PhD, Dae Seog Heo, MD, PhD. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor. JAMA 2014;311(14):1430-1437.
10. MARK A. SOCINSKI, LIZA C.VILLARUZ, JEFFREY ROSS. Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. The Oncologist 2016;21:1–9.
11. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumour specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.